Uptake of radiolabelled α-fetoprotein by experimental mammary adenocarcinoma and adenoma: in vivo and in vitro studies

Nuclear Medicine Communications

Volumn 24, Issue 3, 2003, Pages 297-303

  Mirowski, M ^a   SWITALSKA J ^a   Wiercioch, R ^b   Byszewska, E ^b   Niewiadomska, H ^b   Michalska, M ^b  

^a Radioisotope Centre POLATOM   (United States)

^b Medical University   (United States)

Author keywords

Mammary adenocarcinoma; Mammary adenoma; fetoprotein; fetoprotein receptor

Indexed keywords

ALPHA FETOPROTEIN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ADENOCARCINOMA; ADENOMA; ANIMAL; ARTICLE; C3H MOUSE; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; MOUSE; PATHOLOGY; RAT; SCINTISCANNING; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL;

ADENOCARCINOMA; ADENOMA; ALPHA-FETOPROTEINS; ANIMALS; BIOLOGICAL TRANSPORT; FEMALE; HUMANS; IODINE RADIOISOTOPES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0042261465     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200303000-00010     Document Type: Article

References (32)

1. Suzuki Y, Zeng CQY, Alpert E. Isolation and partial characterization of a specific alpha-fetoprotein receptor on human monocytes. J Clin Invest 1992; 90: 1530-1536.
2. Lorenzo HCh, Geuskens M, Macho A, et al. Alpha-fetoprotein binding and uptake by primary cultures of human skeletal muscle. Tumor Biol 1996; 17: 251-260.
3. Torres JM, Geuskens M, Uriel J. Activated human T lymphocytes express albumin binding proteins which cross-react with alpha-fetoprotein. Eur J Cell Biol 1992; 57: 222-228.
4. Villacampa MJ, Moro R, Naval J, Failly-Crepin C, Lampreave F, Uriel J. Alpha-fetoprotein receptors in human breast cancer cell line. Biochem Biophys Res Commun 1984; 122: 1322-1327.
5. Uriel J, Laborda J, Naval J, Geuskens M. Alpha-fetoprotein receptors in malignant cells: an overview. In: Mizejewski GJ, Jacobson HI, eds. Biological activities of alpha-fetoproteins, Vol. 2. Boca Raton, FL: CRC, 1989: 103-117.
6. Torres JM, Geuskens M, Uriel J. Receptor-mediated endocytosis and recycling of alpha-fetoprotein in human B-lymphoma and T-leukemia cells. Int J Cancer 1991; 47: 110-117.
7. Mizejewski GJ. Alpha-fetoprotein binding proteins: implications for transmembrane passage and subcellular localization. Minireview. Life Sci 1995; 56: 1-9.
8. Uriel J, Failly-Crepin C, Villacampa MJ, Pineiro A, Geuskens M. Incorporation of alpha-fetoprotein by the MCF-7 human breast cancer cell line. Tumor Biol 1984; 5: 41-51.
9. Uriel J, Villecampa M-J, Moro R, Naval J, Failly-Crepin Ch. Uptake of radiolabeled-fetoprotein by mouse mammary carcinomas and its usefulness in tumor scintigraphy. Cancer Res 1984; 44: 5314-5319.
10. Kanevsky V, Pozdnyakova LP, Aksenova OA, Severin SE, Katukov VYu, Severin ES. Isolation and characterization of AFP-binding proteins from tumor and fetal human tissues. Biochem Mol Biol Interact 1997; 41: 1143-1151.
11. Torres JM. Expression of alpha-fetoprotein receptors by human T-lymphocytes during blastic transformation. Mol Immunol 1989; 26: 851-857.
12. Severin SE, Moskaleva E, Shmyrev II, et al. Alpha-fetoprotein mediated targeting of anti-cancer drugs to tumor cells in vitro. Biochem Mol Biol Interact 1995; 37: 385-392.
13. Severin SE. In vivo anti-tumor activity of cytotoxic drugs conjugated with human alpha-fetoprotein. Tumor Targeting 1996; 2: 299-306.
14. Thompson HJ, Meeker DL. Induction of mammary gland carcinomas by the subcutaneous injection of 1-methyl-1-nitrosourea. Cancer Res 1983; 43: 1628-1629.
15. Russo J, Russo JH, van Zwieten MJ, Rogers AE, Gustafson BE. In: Jones TC, Koniski Y, Mohr U, eds. Integument and mammary glands. Monograph series on the pathology of laboratory animals. Berlin: Springer-Verlag, 1988: 275.
16. 131I-labeled human growth hormone of high specific radioactivity. Biochem J 1963; 89: 114-123.
17. Hembrough TA, Vasudevan J, Allietta M, Glass II WF, Gonias SL. A cytokeratin 8 like protein with plasminogen-binding activity is present on the external surface of hepatocytes, HepG2 cells and breast carcinoma cell lines. J Cell Sci 1995; 108: 1071-1082.
18. Prevost G, Provost P, Salle V, Lanson M, Thomas F. A cross-linking assay allows the detection of receptors for the somatostatin analogue, lanreotide, in human breast tumors. Eur J Cancer 1993; 29A: 1589-1592.
19. Gueskens M, Torres JM, Esteban C, Uriel J. Morphological characterization of the pathway of endocytosis and intracellular processing of transferrin and alpha-fetoprotein in human T lymphocytes stimulated with phytohemagglutinin (PHA). Eur J Cell Biol 1989; 50: 418-427.
20. Torres JM, Gueskens M, Uriel J. Activated human T lymphocytes express albumin binding proteins which cross-react with alpha-fetoprotein. Eur J Cell Biol 1992; 57: 222-228.
21. Suzuki Y, Zeng CQY, Alpert EJ. Isolation and partial characterization of a specific alpha-fetoprotein receptor on human monocytes. Clin Invest 1992; 90: 1530-1536.
22. Torres JM, Darracq N, Uriel J. Membrane proteins from lymphoblastoid cells showing cross-affinity for alpha-fetoprotein and albumin. Isolation and characterization. Biochim Biophys Acta 1992; 1159: 60-66.
23. Sarcione EJ, Zlotty M, Delluomo DS, Mizejewski GJ, Jacobson HI. Detection and measurement of alpha-fetoprotein in human breast cancer cytosol after treatment with 0.4 M potassium chloride. Cancer Res 1983; 43: 3739-3741.
24. Biddle W, Sarcione EJ. Specific cytoplasmic alpha-fetoprotein binding protein in MCF-7 human breast cancer cells and primary breast cancer tissue. Br Cancer Res Treat 1987; 10: 279-286.
25. Mirowski M, Walaszek Z, Sherman U, Adams AK, Hanausek M. Demonstration of a 65 kDa tumor-specific phosphoprotein in urine and serum of rats with N-methyl-N-nitrosourea-induced mammary adenocarcinoma. Carcinogenesis 1993; 14: 1659-1664.
26. Gonias ST, Hembrough TA, Sankovic M. Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells. Frontiers Biosci 2001; 6: 1403-1411.
27. Brylinska J, Kwiatkowska J. Laboratory animals. Breeding and experimental methods. Cracow: Universitatis, 1996: 158-167 (in Polish).
28. Garnuszek P, Licinska I, Skierski JS, et al. Biological investigation of the platinum(II)-[*I]iodohistamine complexes of potential synergistic anti-cancer activity. Nucl Med Biol 2002; 29: 169-175.
29. Tesarova P, Kvasnicka J, Umlaufova A, Homolkova H, Jirsa M, Tesar V. Soluble TNF and IL-2 receptors in patients with breast cancer. Med Sci Monit 2000; 6: 661-667.
30. Lee EJ, Oh EJ, Park YJ, Lee HK, Kim BK. Soluble transferrin receptor (sTfR), ferritin, and sTfR/log ferritin index in anemic patients with nonhematologic malignancy and chronic inflammation. Clin Chem 2002; 48: 1118-1121.
31. Wu JT. C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis, early detection and monitoring patients undergoing Herceptin treatment. Clin Chim Acta 2002; 322: 11-19.
32. Mizejewski GJ, Dias JA, Hauer CR, Henrikson KP, Gierthy J. Alpha-fetoprotein derived synthetic peptides: assay of an estrogen-modifying regulatory segment. Mol Cell Endocrinol 1996; 118: 15-23.